Objective Transforming growth factor-β is considered to play a key role in the process of fi brosis in systemic sclerosis (SSc) and in the development of regulatory T cells (Treg) and pro-infl ammatory Th17 T cells producing interleukin 17 (IL-17) and IL-22. The authors therefore postulated that SSc could be characterised by a marked Treg/Th17 imbalance. Previous works did not distinguish between the different subsets of Treg and the nonregulatory FoxP3 + cells leading to inconsistent results.
INTRODUCTION
Systemic sclerosis (SSc) is an incurable disease characterised by fi brosis of the skin and organs, damage to endothelial cells leading to widespread vasculopathy and immunological abnormalities. 1 Numerous studies have demonstrated the crucial role of several fi brogenic cytokines/growth factors and mediators, such as transforming growth factor-β (TGF-β), in initiating the process of fi brosis and orchestrating interactions among lymphocytes, fi broblasts, endothelial cells and monocytes/ macrophages. 2 Recently, circulating antibodies to platelet-derived growth factor receptors, which EXTENDED REPORT Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions Alexis Mathian, 1, 2, 3 Christophe Parizot, 4 Karim Dorgham, 1, 3 Salim Trad, 2, 3 Laurent Arnaud, 1, 2, 3 Martin Larsen, 1, 3 Makoto Miyara, 1,2,3,4 Miguel Hié, 2 Jean-Charles Piette, 2, 3 Camille Frances, Hans Yssel, 1 Zahir Amoura, 1, 2, 3 Guy Gorochov 1, 3, 4 activate fi broblasts and collagen synthesis, have been identifi ed in SSc. 3 However, the precise triggering event(s) initiating the pathogenic sequence leading to fi brosis remains unknown.
There is growing evidence that T cell proliferation and cytokine secretion play a major role in SSc, [4] [5] [6] [7] [8] [9] suggesting that this condition could be associated with a generally defective control of T cell activation. Naturally occurring CD4 regulatory T cells (Tregs) can suppress the immune response of CD4 and CD8 T cells. FoxP3 is still considered to be the most specifi c marker for Tregs, although its expression can be induced in conventional T cells via activation without conferring suppressive activity. [10] [11] [12] [13] [14] Based on our observations, 14 FoxP3 + CD4 Tregs can be divided into CD4 CD45RA − FoxP3 bright CD25 bright and CD4 CD45RA + FoxP3 + CD25 + fractions, while the remaining CD4 FoxP3 + (ie, CD4 CD45RA − FoxP3 low CD25 + ) include a notable amount of non-regulatory, cytokinesecreting, activated T cells (=non-regulatory FoxP3 + T cells). CD4 CD45RA − FoxP3 bright CD25 bright Tregs are activated, highly suppressive and in vivo proliferating cells defi ned as activated Tregs (aTregs). 14 CD4 CD45RA + FoxP3 + CD25 + Tregs are fully functional, antigen-experienced cells and will therefore be hereafter referred to as resting Tregs (rTregs), 14 rather than naive Tregs. CD45RA + Treg cells represent the main peripheral reservoir of CD45RA − Treg cells. 14 Recently, a new subset of T helper cells was described and named Th17 based on its production of interleukin 17A (IL-17A),-17F and -22. 15 Th17 cells play an important role in tissue damage. TGF-β, in association with infl ammatory cytokines, facilitates Th17 differentiation (reviewed in reference 15 ). TGF-β also plays a key role in the development of Tregs, as it induces differentiation and expansion of CD4 CD25 T regulatory cells from CD4 CD25 − precursors. 16 It has been suggested that the transcription factor aryl hydrocarbon receptor and its ligands might regulate the Treg/Th17 balance by modulating TGF-β signalling within the nucleus. 17 Because it was recently proposed that IL-17 together with TGF-β and IL-6 could be, at least in part, responsible for most prominent features of SSc such as fi broblast proliferation and endothelium activation, 18 we hypothesised that a Treg/Th17 imbalance could be a central component of SSc pathophysiology. On the one hand, normal 19 or increased [20] [21] [22] frequencies of circulating FoxP3-expressing T cells have been Altogether, we conclude from these results that Treg immunosuppressive activity is preserved in SSc patients.
Decreased circulating aTregs in SSc patients
The proportion of FoxP3 + CD4 is similar in SSc patients compared with controls (median (range) 6.42% (2.85 to 28.70) of CD4 T cells vs 7.15% (3.66 to 13.81); p=0.19) (fi gure 2A).
Based on our observations, 14 FoxP3 + CD4 T cells were divided into CD4 CD45RA − FoxP3 bright aTregs (gate c, fi gure 2B), CD4 CD45RA + FoxP3 + rTregs (gate a, fi gure 2B) and nonregulatory CD4 CD45RA − FoxP3 low T cells (gate b, fi gure 2B). Proportions and absolute counts of aTregs are signifi cantly decreased in SSc patients compared with controls (median (range) 0.66% (0.17 to 2.00) of CD4 T cells and 5 (1to17) cells/ mm 3 vs 1.51% (0.79 to 3.03) and 13 cells/mm 3 ; p<0.0001 and p<0.0001, respectively) (fi gure 2C). Percentage of aTregs were correlated with the EScSG activity index (p=0.003, r=0.40) (supplemental fi gure S1), the MRSS (p=0.02, r=0.29) and the serum creatinine level (p=0.04, r=0.28). lSSc patients had signifi cantly less aTregs than dSSc patients (p=0.002) (fi gure 2C). aTregs were independent of disease duration, age, DLCO, ΔDLCO, ΔMRSS, Δserum creatinine, ΔEScSG activity index, the presence of interstitial lung disease and the steroid/ immunosuppressive regimen.
The frequencies of non-regulatory FoxP3 + T cells were similar between groups (fi gure 2C). Yet, among SSc patients, increased frequencies of non-regulatory FoxP3 + T cells correlated with increased serum creatinine levels (p=0.009, r=0.36) (supplemental fi gure S2) but not with any of the other parameters cited above. The proportions of IFNγ-, IL-17-, IL-22-and IL-2-producing cells among non-regulatory FoxP3 + CD4 T cells were similar in controls and SSc (supplemental fi gure S3).
rTregs decrease in late SSc stages
Proportions and absolute counts of rTregs (gate a, fi gure 2B) were signifi cantly reduced in SSc compared with controls (0.72% observed in SSc. However, no clear distinction was made in these studies between activated and rTregs and non-regulatory FoxP3 + cells 14 and, as a result, no clear conclusion can be drawn regarding Treg cell status. On the other hand, IL-17 was reported elevated in the serum of SSc patients. 23 24 This fi nding was not confi rmed in a more recent study, which nevertheless reported drastically increased Th17 frequencies in SSc. 25 Finally, although circulating IL-22-secreting T cells were found associated with interstitial lung disease in SSc, expression of IL-22 has not been previously studied in SSc tissues. 26 Here, we show that Tregs retain suppressive activity in SSc but are reduced in numbers. Furthermore, we document a decline of the circulating aTreg subset with disease progression. At the same time, no Th17 amplifi cation was observed. However, IL-22 was found increased in lesional and non-lesional skin.
PATIENTS, MATERIALS AND METHODS Patients and controls
Blood samples were obtained from 53 consecutive patients with SSc (table 1) .
SSc was diffuse (dSSc) in 35 patients and limited in 18 patients (lSSc). 27 We recorded at the time of blood collection the Modifi ed Rodnan Skin Score (MRSS), 28 the serum creatinine level, the diffusing capacity of the lung for carbon monoxide (DLCO) and the European Scleroderma Study Group (EScSG) activity index that evaluate disease activity using clinical and laboratory items resulting in a score ranging from 0 to 10 (0=no activity; 10=maximal activity). 29 We recorded their change after 12 months (delta=Δ). Disease stages were defi ned as suggested by Steen and Medsger: for early lSSc, disease duration <5 years; for late lSSc, disease duration ≥5 years; for early dSSc, disease duration <3 years; and for late dSSc, disease duration ≥3 years. 30 The control group consists of 24 healthy volunteers matched for age and sex with the SSc group.
Skin biopsies were obtained from nine early SSc patients (eight dSSc and one lSSc) and seven healthy donors undergoing surgery. Thus, 5 mm punch biopsies in clinically affected and unaffected skin were obtained from all nine SSc patients and, in fi ve cases, from transition areas. Treatments are detailed in the supplementary informations. Five patients (9.4%) had previously received cyclophosphamide but at least 1 year elapsed between immunosuppressive treatment and inclusion in the study. Seventeen (32.1%) were on low dose steroids (below 10 mg of prednisone a day) at the time of inclusion in the study.
In vitro culture assays, fl ow cytometry, cytokine detection procedures and statistical analysis. See supplementary informations.
RESULTS

SSc aTregs and rTregs suppress autologous T cell proliferation and cytokine secretion
Live human Tregs cannot be purifi ed using intracellular FoxP3 as a marker. Because there is a linear correlation between CD25 and FoxP3 levels expressed by CD4 CD25 bright T cells, 14 31 circulating aTregs were purifi ed as CD4 CD45RA − CD25 bright T cells (sorting gate c, fi gure 1A). SSc aTregs inhibited autologous, anti-CD3-induced, CD4 CD25 − T-cell proliferation as effi ciently as control aTregs (fi gure 1B,C). SSc rTregs, defi ned as CD4 CD45RA + CD25 + T cells (sorting gate a, fi gure 1A), also proved to be as immunosuppressive as control rTregs (fi gure 1B,C). The percentage of proliferating (ie, Ki-67 + cells) aTregs was similar in SSc patients and in controls (fi gure 1D). Like in controls, rTregs remained non-proliferating in patients (fi gure 1D). SSc Tregs 
A FoxP3 signature associated with active and diffuse disease
In multivariate analysis, the proportions of rTregs (p=0.02), aTregs (p=0.0003) and non-regulatory FoxP3 + T cells (p=0.002) among CD4 T cells were independently associated with the diagnosis of SSc, compared with controls. A higher proportion of aTregs (p=0.01), but not of other FoxP3 + subsets, was independently associated with the diagnosis of dSSc versus lSSc.
Hierarchical cluster analysis based on FoxP3 + subsets proportions resulted in the delineation of two clusters within SSc patients. Cluster #1 patients (n=20) have more likely dSSc (p=0.023), signifi cantly higher proportions of rTregs (p=0.03), aTregs (p<0.0001), non-regulatory FoxP3 + T cells (p<0.0001), MRSS (p=0.049) and EScSG activity scores (p=0.014) than cluster #2 patients (n=33) (fi gure 3). Validity and reproducibility of this partition in two clusters were assessed using non-hierarchical k-means cluster analysis (κ agreement value=0.96).
FoxP3 + T cells are not redistributed to the skin of SSc patients
Histological analysis of affected areas of SSc skin showed small pericapillary lymphocytic infi ltrates (data not shown). Real time quantitative PCR showed that CD3 was more abundant in SSc skin (supplemental fi gure S5). Yet, immunohistological analyses, using anti-CD4 and anti-FoxP3 antibodies 31 did not reveal the presence of FoxP3 + cells in SSc-associated skin sclerosis (data not shown). We rather observed that FoxP3 transcripts were less abundant in SSc than in control skin, as evaluated by real time quantitative PCR (supplemental fi gure S6).
IL-17 production is similar in SSc patients and controls
IL-17 could only be detected in the serum of fi ve out of 28 SSc patients and was not above detection level in any of the 15 controls (p=0.15). No differences in IL-17 serum levels were found between SSc patients at late and early disease stage (p=0.57) (fi gure 4B, left). In addition, IL-17 levels also did not differ between lSSc and dSSc (data not shown). Considering that IL-17 serum detection might not be sensitive enough to evaluate the Th17 axis in SSc, we measured the percentage of circulating CD4 T cells expressing IL-17 following CD3/ CD28 stimulation. No signifi cant differences between controls and SSc patients were observed (0.4% (0.1 to 1.6) and 0.5% (0.1 to 2.0) of CD4 T cells, respectively, p=0.99) (fi gure 4A). The frequencies of Th17 cells did not signifi cantly differ between early and late SSc patients (p=0.55) (fi gure 4A). Finally, as shown in fi gure 4C, left, IL-17 transcripts were not more abundant in SSc patients than in controls. 
Increased IL-22 expression in SSc
We investigated other putative Th17-associated markers. Global proportions of circulating IL-22-secreting cells were not found to be increased in SSc patients, as compared with controls (p=0.48). Twelve out of 29 SSc patients had serum IL-22 levels above detection threshold, as compared with two out of 15 controls (p=0.08). A signifi cantly increased proportion of late SSc patients (nine out of 13 patients) had circulating IL-22 levels above detection threshold, as compared with early disease stage SSc patients (three out of 16 patients) (p=0.02, fi gure 4B, right). No difference was found between lSSc and dSSc (data not shown). Finally, IL-22 transcripts were signifi cantly more abundant in SSc skin, as compared with healthy skin samples (p=0.005) (fi gure 4C, right). Of note, β-actin levels were similar in SSc and control skin (data not shown). Results were confi rmed using RS9 (GenBank accession # NM_001013) as other endogenous gene reference (data not shown). IL-22 transcriptional levels were similar in clinically affected areas, in what was considered unaffected areas as well as in transition areas between the former two regions (fi gure 4C, right).
DISCUSSION
The assessment of Treg cell performed in the present study relies on a functional delineation of FoxP3-expressing CD4 T cells allowing at the same time to discriminate aTregs, rTregs and non-regulatory FoxP3 + T cells. 14 These distinctions were not clearly made in previous studies addressing the same issue. [19] [20] [21] [22] We report that aTregs are decreased in SSc patients irrespective of disease stage whereas the decline in rTregs is mainly manifest in late stages. Nevertheless, SSc aTregs and rTregs retain their ability to block CD4 CD25 − T cell proliferation and to inhibit cytokine secretion. Thus, contrary to what has been reported previously, there is neither quantitative expansion [20] [21] [22] nor qualitative defi ciency 20 33 34 of bona fi de Tregs in SSc. It cannot be concluded either that Treg counts are unchanged in SSc patients compared with controls. 19 These discrepancies are most likely related to the observation that FoxP3 expression can be induced in conventional T cells via activation without conferring suppressive activity. [10] [11] [12] [13] [14] Since previous studies in SSc were based on the analysis of global FoxP3 expression of CD4 T cells and/or did not discriminate between the different subsets of Treg, [19] [20] [21] [22] relatively abundant non-regulatory FoxP3 + CD4 T cells could have masked the modifi cations of the more discrete Treg subsets.
The quantitative Treg defect observed could account for the T cell activation and expansion associated with SSc. [4] [5] [6] [7] [8] [9] The reasons of this decline are still speculative. Numerous studies have demonstrated the central role of TGF-β in SSc. 2 This cytokine has also been found to play a key role in the development of Tregs, as it induces differentiation and expansion of CD4 CD25 T regulatory cells from CD4 CD25 − precursors. 16 35 36 Therefore, in the context of increased TGF-β levels, like in SSc, an increased pool of Tregs could have been expected at all stages. Interestingly, we indeed observed through hierarchical analysis of FoxP3+ subsets that patients with diffuse and/or active SSc have relatively higher proportions of both regulatory and non-regulatory FoxP3 + T cells, compared with patients with less active disease. However, long term and strong stimulation by TGF-β over Treg cells could result in a high turn-over and differentiation of the latter and, consequently, in an exhaustion of the Treg pool. This could explain why we also found a negative correlation between circulating rTregs numbers and the time elapsed since disease onset, while rTreg levels were not correlated with age. As it was recently shown that human rTreg can convert into aTreg in vivo, 14 it is tempting to conclude that repetitive TCR-mediated stimulation could have resulted in the peripheral conversion of most natural rTreg cells into antigen-experienced aTregs.
Altogether, there is a quantitative Treg defect in SSc that is less pronounced in diffuse and/or active disease, this apparent paradox being likely the result of a compensatory, but inefficient, amplifi cation of regulatory cells in the context of active infl ammation.
It was recently confi rmed that TGF-β, along with IL-23 and pro-infl ammatory cytokines, is essential to the differentiation of the Th17 lineage. 37 In a TGF-β-related condition like SSc, it could therefore have been expected to observe an amplifi cation of Th17 cells. Indeed, increased IL-17 production by SSc T cells has been reported, especially in early stages of the disease. 23 24 In a recent study, very high frequencies of circulating Th17 cells (up to 40% of CD4 CD45RO + cells and up to 20% of CD4 CD45RA + cells) were reported in SSc patients. 25 This result could be due to a different analysis strategy as the study was done on purifi ed CD3 cells and not with unfractioned PBMC. In our own study, we did not fi nd signifi cantly elevated IL-17 levels neither by ELISA nor by intracellular fl ow cytometry, It should be noted that in the study reported by Murata et al, most of the IL-17 serum levels were below the minimum signifi cant detection level of their ELISA assay (5 pg/ml). 24 The reasons for the discrepancy between our results and the one by Kurasawa et al are less clear. 23 In an effort to use a more sensitive and possibly more appropriate assay, we quantifi ed IL-17 transcripts in SSc skin lesions. IL-17 mRNA levels were not found elevated. We can only speculate that Kurasawa et al had access to patients in their very early stage of the disease in order to explain the discrepancy between their results and ours. Nevertheless, it is fair to conclude that in SSc, Treg depletion is not associated with a concomitant amplifi cation of Th17 cells.
Even if IL-22 is mostly expressed by Th17 cells, 38 its expression differs from that of IL-17 39 and recently, a novel subset of IL-22-, but not IL-17-producing T cells, with skin homing potential was described in healthy subjects and in infl amed tissues. 40 However, the existence of a truly separate 'Th22' subset remains unclear. IL-22 is a key cytokine in the regulation of infl ammatory responses, particularly in the skin where it mediates keratinocyte migration and differentiation and epithelial hyperplasia leading to the epidermal remodelling and the thickening of the epidermis with dermal infi ltration of macrophages, some of the pathological features seen in SSc skin. [39] [40] [41] [42] In the present study, we confi rm the existence in SSc patients and in healthy subjects of a CD4 IL-17 -IL-22 + circulating subset. 43 44 It was impossible for ethical reasons to obtain enough SSc skin material to perform cytofl uorometric analysis on lesional T cells in order to directly confi rm their expected skin tropism. 43 44 We were also unable to set up immunohistochemistry staining to confi rm the presence of Th22 cells in situ. However, the observation that IL-22, but not IL-17 transcripts, were found more likely elevated in SSc skin samples than in normal skin (fi gure 3C) is strongly suggestive of the presence of 'IL-22-producing cells only' associated with SSc.
Finally, it should be noted that we found elevated IL-22 transcripts in SSc lesions and in apparently unaffected areas. An SSc-associated gene expression pattern was also observed both in clinically affected and clinically unaffected skin using DNA microarrays. 45 Both results further emphasise the systemic nature of this condition that has covert manifestations in early stages of the disease and in apparently unaffected organs.
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